Ralaniten
Ralaniten (also known as EPI-002) is a nonsteroidal antiandrogen (NSAA) which is under development for the treatment of prostate cancer. It acts as an androgen receptor antagonist and is targeted at the N-terminal domain of the receptor.
Mechanism of Action[edit | edit source]
Ralaniten works by binding to the N-terminal domain of the androgen receptor. This is a unique mechanism of action compared to other NSAAs, which typically target the ligand-binding domain of the receptor. By targeting the N-terminal domain, Ralaniten can inhibit both the receptor's transcriptional activity and its ability to bind to androgens.
Clinical Trials[edit | edit source]
Ralaniten has been studied in phase I and II clinical trials for the treatment of prostate cancer. In these trials, it has shown promise in treating patients with castration-resistant prostate cancer, a form of the disease that is resistant to other forms of treatment.
Side Effects[edit | edit source]
As with all medications, Ralaniten may cause side effects. These can include nausea, fatigue, and diarrhea. However, these side effects are generally mild and manageable.
Future Research[edit | edit source]
Further research is needed to fully understand the potential of Ralaniten in treating prostate cancer. This includes more extensive clinical trials and studies into its long-term effects.
See Also[edit | edit source]
Ralaniten Resources | ||
---|---|---|
|
|
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD